2-吡咯烷-1-甲基哌啶 | 100158-63-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-吡咯烷-1-甲基哌啶
• 中文别名: 2-((1-吡咯烷基)甲基)哌啶
• 英文名称: 2-[(1-Pyrrolidinyl)methyl]piperidine
• 英文别名: 2-((pyrrolidin-1-yl)methyl)piperidine；2-[(1-Pyrrolidinyl)methyl]piperdine；2-Pyrrolidin-1-ylmethyl-piperidine；2-(pyrrolidin-1-ylmethyl)piperidine
• CAS: 100158-63-2
• 化学式: C₁₀H₂₀N₂
• mdl: MFCD03426449
• 分子量: 168.282
• InChiKey: GJJCBYJAVZCDCB-UHFFFAOYSA-N

物化性质

• 沸点：
  243℃
• 密度：
  0.956
• 闪点：
  93℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-吡咯烷-1-甲基哌啶 、 2-(4-硝基苯基)乙酰氯 在 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 2-(4-Nitrophenyl)-1-[2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]ethanone
  参考文献：
  名称：

  （2S）-1-（芳基乙酰基）-2-（氨基甲基）哌啶衍生物：新颖的高选择性κ阿片类镇痛药。

  摘要：

  本文描述了新型的1-（芳基乙酰基）-2-（氨基甲基）哌啶衍生物的合成和构效关系，作为κ阿片类镇痛药。通过计算研究和1H NMR定义了具有60度扭转角（N1C2C7N8）的药效团的活性构象。芳香族部分取代的定量结构-活性关系研究表明，对位和/或间位存在吸电子和亲脂性取代基是良好的镇痛活性和κ亲和力所必需的。铅化合物（2S）-1-[（（3,4-二氯苯基）乙酰基] -2-（吡咯烷-1-基甲基）哌啶盐酸盐和（2S）-1- [4-（三氟甲基）苯基]乙酰基] -2 -（吡咯烷-1-基甲基）哌啶盐酸盐的Kappa / mu选择性最高（分别为6500：1和4100：1）以及迄今为止鉴定出的最有力的（κκ0.24和0.57 nM）κ配体。在抗伤害感受的小鼠甩尾模型中，化合物14（ED50 = 0.05 mg / kg sc）的效力是吗啡的25倍，效力是标准Kappa配体U-50488的16倍。

  DOI：

  10.1021/jm00105a061
• 作为产物：
  描述：

  2-(吡咯烷-1-基羰基)哌啶 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-吡咯烷-1-甲基哌啶
  参考文献：
  名称：

  2-氨基甲基哌啶类化合物作为新型尿紧张素-II受体拮抗剂。

  摘要：

  已经发现了一系列2-氨基甲基哌啶作为新型尿素-II受体拮抗剂。描述了合成，初始结构-活性关系以及初始命中的优化，从而确定了有效的，跨物种活性和功能性尿紧张素-II受体拮抗剂，例如1a和11a。

  DOI：

  10.1016/j.bmcl.2008.03.078

文献信息

• Analgesic thiomorpholins their preparation, and pharmaceutical
  申请人：Sankyo Company Limited

  公开号：US05021413A1

  公开（公告）日：1991-06-04

  Analgesic compounds are of the general formula (I): ##STR1## in which, R.sup.1 and R.sup.2 each represents hydrogen or C.sub.1 -C.sub.6 alkyl, or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a heterocycle; E represents methylene, sulfur, oxygen or imino group optionally substituted with C.sub.1 -C.sub.6 alkyl or aralkyl; ring A is aryl or heteroaryl ring, optionally substituted; R.sup.3 is hydrogen or C.sub.1 -C.sub.6 alkyl and R.sup.4 is hydrogen or R.sup.3 and R.sup.4 together represent a group of formula (IV): --(CR.sup.a R.sup.a).sub.m --C(.dbd.Y)-- (IV) (wherein R.sup.a and R.sup.a is C.sub.1 -C.sub.6 alkyl or hydrogen, up to a maximum of 3 alkyl groups, m is 1, 2, or 3, and Y is two hydrogens or oxygen); provided that when E represents a methylene group, then R.sup.3 is a C.sub.1 -C.sub.6 alkyl group or R.sup.3 and R.sup.4 together represent a group of the formula (IV).

  镇痛化合物的一般式为（I）：##STR1## 在其中，R.sup.1和R.sup.2分别代表氢或C.sub.1-C.sub.6烷基，或者R.sup.1和R.sup.2与它们连接的氮原子一起形成杂环；E代表亚甲基、硫、氧或亚胺基，可选择地用C.sub.1-C.sub.6烷基或芳基取代；环A是芳基或杂芳基环，可选择地取代；R.sup.3是氢或C.sub.1-C.sub.6烷基，R.sup.4是氢或R.sup.3和R.sup.4一起代表式（IV）的基团：--(CR.sup.aR.sup.a).sub.m--C(.dbd.Y)--（IV）（其中R.sup.a和R.sup.a是C.sub.1-C.sub.6烷基或氢，最多有3个烷基基团，m为1、2或3，Y为两个氢或氧）；但是当E代表亚甲基时，R.sup.3是C.sub.1-C.sub.6烷基基团或R.sup.3和R.sup.4一起代表式（IV）的基团。
• CATALYST FOR ASYMMETRIC HYDROGENATION
  申请人：MAEDA Hironori

  公开号：US20100324338A1

  公开（公告）日：2010-12-23

  This invention aims at providing a catalyst for producing an optically active aldehyde or an optically active ketone, which is an optically active carbonyl compound, by carrying out selective asymmetric hydrogenation of an α,β-unsaturated carbonyl compound, particularly a catalyst which is insoluble in a reaction mixture for obtaining optically active citronellal which is useful as a flavor or fragrance, by carrying out selective asymmetric hydrogenation of citral, geranial or neral; and a method for producing a corresponding optically active carbonyl compound. The invention relates to a catalyst for asymmetric hydrogenation of an α,β-unsaturated carbonyl compound, which comprises a powder of at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table, or a metal-supported substance in which at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table is supported on a support, an optically active cyclic nitrogen-containing compound and an acid.

  这项发明旨在通过对α，β-不饱和羰基化合物进行选择性不对称加氢，特别是通过对柠檬醛、香叶醛或柠檬醛进行选择性不对称加氢，从而提供用作香料或香精的有用的光学活性香茅醛的催化剂，该香茅醛是一种光学活性羰基化合物；以及生产相应的光学活性羰基化合物的方法。该发明涉及一种用于不对称加氢α，β-不饱和羰基化合物的催化剂，其包括来自周期表第8至第10族金属中至少一种金属的粉末，或者至少一种来自周期表第8至第10族金属的金属负载物质，该金属负载在一种支撑物上，还包括光学活性的含氮环化合物和酸。
• Condensed diazepinones, their compositions and methods of use as
  申请人：Dr. Karl Thomae GmbH

  公开号：US04550107A1

  公开（公告）日：1985-10-29

  Disclosed are novel condensed diazepinones of formula I ##STR1## wherein B is a fused ring selected from ##STR2## X is --CH-- or, when B is ortho-phenylene, X can also be nitrogen; A.sub.1 is C.sub.1 -C.sub.2 alkylene; A.sub.2 is C.sub.1 -C.sub.2 when it is in the 2-position relative to the saturated heterocyclic ring nitrogen or a single bond or methylene when it is in the 3- or 4-position; R.sub.1 is C.sub.1 -C.sub.3 alkyl; R.sub.2 is C.sub.1 -C.sub.7 alkyl, optionally hydroxy-substituted on at least one of its second to seventh carbon, or C.sub.3 -C.sub.7 cycloalkyl, optionally hydroxy substituted, or C.sub.3 -C.sub.7 cycloalkylmethyl; or R.sub.1 and R.sub.2 can, together with the nitrogen therebetween, be a 4- to 7-membered saturated monocyclic, heterocyclic ring which can optionally include an oxygen or N--CH.sub.3 ; R.sub.3 is hydrogen, chlorine, or methyl; R.sub.4 is hydrogen or C.sub.1 -C.sub.4 alkyl, R.sub.5 is hydrogen, chlorine or C.sub.1 -C.sub.4 alkyl; and Z is a single bond, oxygen, methylene or 1,2-ethylene; and NR.sub.1 R.sub.2 --N oxides and nontoxic, pharmaceutically acceptable addition salts thereof. Also disclosed are pyrrolobenzodiazepinone intermediates, pharmaceutical compositions containing the condensed diazepinones and methods of using them to treat cardiovascular disorders, particularly bradycardia and bradyarrhythmia.

  揭示了式I的新型缩合二氮杂环酮##STR1##其中B是从##STR2##中选择的融合环；X是--CH--或者当B是邻苯二甲烷时，X也可以是氮；A.sub.1是C.sub.1-C.sub.2烷基；A.sub.2是C.sub.1-C.sub.2，当它相对于饱和杂环环氮位于2位时，或者是单键或亚甲基，当它位于3位或4位时；R.sub.1是C.sub.1-C.sub.3烷基；R.sub.2是C.sub.1-C.sub.7烷基，其至少在第二到第七碳上可选择地被羟基取代，或者是C.sub.3-C.sub.7环烷基，可选择地被羟基取代，或者是C.sub.3-C.sub.7环烷基甲基；或者R.sub.1和R.sub.2可以与其之间的氮一起形成一个4到7成员的饱和单环杂环，可选择地包括氧或N--CH.sub.3；R.sub.3是氢、氯或甲基；R.sub.4是氢或C.sub.1-C.sub.4烷基，R.sub.5是氢、氯或C.sub.1-C.sub.4烷基；Z是单键、氧、亚甲基或1,2-乙烯基；以及NR.sub.1 R.sub.2 --N氧化物和其无毒、药学上可接受的加合盐。还揭示了吡咯苯二氮杂环酮中间体、含有缩合二氮杂环酮的药物组合物以及使用它们治疗心血管疾病，特别是心动过缓和心动过缓性心律失常的方法。
• Process for Production of Optically Active Quinuclidinols
  申请人：Noyori Ryoji

  公开号：US20090216019A1

  公开（公告）日：2009-08-27

  A novel ruthenium complex which is a highly efficient catalyst useful for the production of optically active 3-quinuclidinols, and a process for production of optically active 3-quinuclidinols using the ruthenium complex as a catalyst, where the optically active 3-quinuclidinols are useful as an optically active, physiologically active compound utilized in medicines and agrichemicals or as a synthetic intermediate such as a liquid crystal material.

  一种新颖的钌配合物，是一种高效催化剂，可用于生产光学活性的3-喹诺啉醇，并且提供一种以该钌配合物为催化剂生产光学活性3-喹诺啉醇的方法，其中光学活性的3-喹诺啉醇可用作光学活性、生理活性的化合物，用于药物和农药，或者作为合成中间体，如液晶材料。
• Use of heterocyclic derivatives as kappa-opioid receptor agonists in the treatment of cerebral ischaemia
  申请人：GLAXO GROUP LIMITED

  公开号：EP0330468A3

  公开（公告）日：1991-04-03

  The invention relates to the use of certain heterocyclic compounds which act as kappa receptor agonists in the treatment of cerebral ischaemia.

  该发明涉及使用某些杂环化合物作为kappa受体激动剂来治疗脑缺血。